In this month's Q&A, Arvind Rao, PhD, talks with contributing editor Tanuja Koppal, PhD, about how artificial intelligence will likely impact diagnostics development
When cleared, Fujirebio’s FDA-designated breakthrough device is expected to be among the first commercially available in vitro diagnostics for patients being evaluated for Alzheimer’s disease in the US